We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Hammerhead ribozyme targeting human hypoxia inducible factor-1alpha gene effectively attenuates HeLa xenograft tumors.
Surgical Neurology 2009 August
BACKGROUND: Hypoxia inducible factor l is a heterodimeric transcription factor that plays an important role in oxygen homeostasis. A good body of evidence indicates that overexpression of HIF-1alpha driven by intratumoral hypoxia can transactivate genes essential for energy metabolism, erythropoiesis, and vascular development, which is directly involved in cancer progression. Overexpressed HIF-1alpha also has a considerably reversed clinical correlation with treatment efficacy as well as mortality of cancers.
METHODS: We took the advantage of the hammerhead ribozyme that specifically targeted 1762-1778 nt of HIF-1alpha messenger RNA.
RESULTS: The designed ribozyme could cleave its substrate HIF-1alpha messenger RNA in both in vitro and in intracellular cleavage assays. More interesting, the synthetic ribozyme RNA administered to HeLa xenograft large tumor could effectively inhibit its angiogenesis and tumor growth.
CONCLUSION: It is reasonable to speculate that down-regulation of HIF-1alpha activity could be a potential mechanism useful to prevent survival or angiogenic activity of various solid tumors.
METHODS: We took the advantage of the hammerhead ribozyme that specifically targeted 1762-1778 nt of HIF-1alpha messenger RNA.
RESULTS: The designed ribozyme could cleave its substrate HIF-1alpha messenger RNA in both in vitro and in intracellular cleavage assays. More interesting, the synthetic ribozyme RNA administered to HeLa xenograft large tumor could effectively inhibit its angiogenesis and tumor growth.
CONCLUSION: It is reasonable to speculate that down-regulation of HIF-1alpha activity could be a potential mechanism useful to prevent survival or angiogenic activity of various solid tumors.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app